Quick Answer
BioAge Labs, Inc. reported Stockholders Equity of $272.05 million for fiscal year 2025.
BioAge Labs, Inc. Stockholders Equity — Annual History
| Fiscal Year | Stockholders Equity | YoY Change |
|---|---|---|
| 2025 | $272.05M | -15.8% |
| 2024 | $323.13M | +286.4% |
| 2023 | -$173.40M | -54.0% |
| 2022 | -$112.56M | — |
Quarterly Stockholders Equity
| Quarter Ending | Stockholders Equity | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $277.46M | -11.6% | -5.9% |
| June 30, 2025 | $294.78M | +249.5% | -5.9% |
| March 31, 2025 | $313.17M | +268.8% | -3.1% |
| December 31, 2024 | $323.13M | +286.4% | +3.0% |
| September 30, 2024 | $313.75M | +304.9% | +259.2% |
| June 30, 2024 | -$197.13M | -41.5% | -6.3% |
| March 31, 2024 | -$185.51M | -50.9% | -7.0% |
| December 31, 2023 | -$173.40M | -54.0% | -13.2% |
- BioAge Labs, Inc. showed a decrease of -15.8% in Stockholders Equity compared to the prior fiscal year.
- Over the 2022–2025 period, BioAge Labs, Inc.’s stockholders equity has grown by 341.7% (from -$112.56 million to $272.05 million).
- The most recent figure is from BioAge Labs, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 24, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: